Tokyo, Japan

Mitsuru Ooizumi


Average Co-Inventor Count = 6.9

ph-index = 3

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2007-2009

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Mitsuru Ooizumi: Innovator in Pyrimidone Derivatives

Introduction

Mitsuru Ooizumi is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of pyrimidone derivatives. With a total of 3 patents to his name, his work focuses on compounds that exhibit inhibitory activity against tau protein kinase 1.

Latest Patents

His latest patents include innovative 3-substituted-4-pyrimidone derivatives. These derivatives are represented by a specific formula and are characterized by their potential therapeutic effects. The compounds are designed to inhibit tau protein kinase 1, which is crucial in various neurological conditions. The structural components of these derivatives include C-Calkyl groups and various aromatic and heterocyclic rings, showcasing a complex and versatile chemical architecture.

Career Highlights

Mitsuru Ooizumi has had a distinguished career, working with prominent companies such as Mitsubishi Pharma Corporation and Sanofi-Synthelabo. His experience in these organizations has allowed him to refine his expertise in pharmaceutical research and development. His contributions have been instrumental in advancing the understanding and application of pyrimidone derivatives in medicine.

Collaborations

Some of his notable coworkers include Masahiro Okuyama and Fumiaki Uehara. Their collaborative efforts have further enriched the research landscape in which Ooizumi operates.

Conclusion

Mitsuru Ooizumi stands out as a key figure in the innovation of pyrimidone derivatives, contributing valuable insights and advancements in medicinal chemistry. His work continues to influence the development of therapeutic agents aimed at treating neurological disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…